. 2022 Mar 5;S2405-8033(22)00024-3.
doi: 10.1016/j.trecan.2022.01.017.
Online ahead of print.
Affiliations
- PMID: 35260379
- DOI: 10.1016/j.trecan.2022.01.017
Abstract
Substantial preclinical evidence demonstrates the antiproliferative, cytotoxic, and antimetastatic properties of plant-derived cannabinoids (phytocannabinoids) such as cannabidiol and tetrahydrocannabinol. The cumulative body of research into the intracellular mechanisms and phenotypic effects of these compounds supports a logical, judicious progression to large-scale phase II/III clinical trials in certain cancer types to truly assess the efficacy of phytocannabinoids as anticancer agents.
Keywords: cancer, cannabinoids, clinical trials.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors have no interests to declare.
